Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BHSENYSE:IKTNASDAQ:IZTCNYSE:PLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHSEBull Horn$9.97$9.63▼$11.19$61.14M-0.0168,771 shs1.18 million shsIKTInhibikase Therapeutics$1.62-1.8%$1.96$1.12▼$4.20$120.43M0.94273,195 shs7.06 million shsIZTCInvizyne Technologies$9.73-5.0%$12.66$8.50▼$23.00$60.80MN/A37,647 shs69,136 shsPLXProtalix BioTherapeutics$1.54+6.2%$1.94$0.82▼$3.10$122.60M-0.2611,752 shs12.69 million shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHSEBull Horn0.00%0.00%0.00%0.00%0.00%IKTInhibikase Therapeutics-1.82%-2.41%-20.59%-29.26%+14.89%IZTCInvizyne Technologies-5.03%-21.25%-30.48%-2.65%+972,539,900.00%PLXProtalix BioTherapeutics+6.21%+10.00%-3.14%-40.31%+25.20%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBHSEBull HornN/AN/AN/AN/AN/AN/AN/AN/AIKTInhibikase Therapeutics1.5216 of 5 stars3.31.00.00.00.00.01.3IZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/AN/AN/APLXProtalix BioTherapeutics2.4172 of 5 stars3.53.00.00.00.60.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHSEBull Horn 0.00N/AN/AN/AIKTInhibikase Therapeutics 2.50Moderate Buy$6.50301.23% UpsideIZTCInvizyne Technologies 0.00N/AN/AN/APLXProtalix BioTherapeutics 3.00Buy$15.00874.03% UpsideCurrent Analyst Ratings BreakdownLatest BHSE, IKT, PLX, and IZTC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2025IKTInhibikase TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHSEBull HornN/AN/AN/A7.36($0.72) per shareN/AIKTInhibikase Therapeutics$260K463.21N/AN/A$1.78 per share0.91IZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/APLXProtalix BioTherapeutics$59.76M2.05$0.09 per share17.80$0.47 per share3.28Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHSEBull Horn$15.23MN/A0.00N/AN/AN/A-119.46%9.08%N/AIKTInhibikase Therapeutics-$19.03M-$2.67N/AN/AN/AN/A-350.63%-201.82%N/AIZTCInvizyne TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/APLXProtalix BioTherapeutics$8.31M$0.04N/A4.97N/A-21.03%-30.89%-11.74%N/ALatest BHSE, IKT, PLX, and IZTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1PLXProtalix BioTherapeuticsN/A-$0.05N/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBHSEBull HornN/AN/AN/AN/AN/AIKTInhibikase TherapeuticsN/AN/AN/AN/AN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/APLXProtalix BioTherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHSEBull HornN/A0.130.13IKTInhibikase TherapeuticsN/A0.850.85IZTCInvizyne TechnologiesN/AN/AN/APLXProtalix BioTherapeuticsN/A1.981.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHSEBull Horn74.95%IKTInhibikase Therapeutics3.81%IZTCInvizyne TechnologiesN/APLXProtalix BioTherapeutics16.53%Insider OwnershipCompanyInsider OwnershipBHSEBull Horn36.60%IKTInhibikase Therapeutics7.30%IZTCInvizyne TechnologiesN/APLXProtalix BioTherapeutics6.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHSEBull Horn25.12 million3.24 millionNot OptionableIKTInhibikase Therapeutics674.34 million66.18 millionNot OptionableIZTCInvizyne Technologies296.25 millionN/AN/APLXProtalix BioTherapeutics20079.61 million69.00 millionOptionableBHSE, IKT, PLX, and IZTC HeadlinesRecent News About These CompaniesNorthern Trust Corp Has $1.38 Million Stock Position in Protalix BioTherapeutics, Inc. (NYSE:PLX)May 29, 2025 | marketbeat.comProtalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYCMay 14, 2025 | finance.yahoo.comPLX: First Quarter ResultsMay 13, 2025 | msn.comEarnings call transcript: Protalix Q1 2025 results miss forecasts, stock plungesMay 10, 2025 | uk.investing.comProtalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2025 Earnings Call TranscriptMay 10, 2025 | insidermonkey.comProtalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business ResultsMay 10, 2025 | finanznachrichten.deProtalix BioTherapeutics Q1 Earnings PreviewMay 10, 2025 | msn.com1PLX : Uncovering Potential: Protalix BioTherapeutics's Earnings PreviewMay 10, 2025 | benzinga.comProtalix BioTherapeutics, Inc. (PLX) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comProtalix eyes Phase II gout trial later this year following solid Q1 revenue growthMay 9, 2025 | proactiveinvestors.comProtalix BioTherapeutics Reports First Quarter 2025 Financial and Business ResultsMay 9, 2025 | prnewswire.comProtalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025May 6, 2025 | seekingalpha.comWhy Protalix BioTherapeutics, Inc.’s (PLX) Stock Is Up 8.71%April 15, 2025 | aaii.comAProtalix BioTherapeutics Is A Strong Buy With Increasing Revenues And A Promising PipelineApril 10, 2025 | seekingalpha.comProtalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025March 24, 2025 | finance.yahoo.comIs Protalix BioTherapeutics (PLX) The High Growth Low Debt Stock to Invest in Now?March 22, 2025 | msn.comProtalix Biotherapeutics chairman discusses breakthrough in gout treatment, drug pipeline - ICYMIMarch 21, 2025 | proactiveinvestors.comProtalix Stock (PLX) Grabbing Attention with Record Revenue SurgeMarch 20, 2025 | markets.businessinsider.comProtalix BioTherapeutics, Inc. (PLX) Q4 2024 Earnings Call TranscriptMarch 19, 2025 | seekingalpha.comEarnings call transcript: Protalix Q4 2024 sees 31% revenue growthMarch 19, 2025 | uk.investing.comAmended: Protalix Annual Earnings FallMarch 19, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBHSE, IKT, PLX, and IZTC Company DescriptionsBull Horn NASDAQ:BHSEBull Horn Holdings Corp. does not have significant operations. It intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the sports, entertainment, and brands sectors. The company was incorporated in 2018 and is based in Miami Beach, Florida.Inhibikase Therapeutics NYSE:IKT$1.62 -0.03 (-1.82%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$1.54 -0.08 (-4.63%) As of 06/27/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.Invizyne Technologies NASDAQ:IZTC$9.73 -0.51 (-5.03%) As of 06/26/2025Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.Protalix BioTherapeutics NYSE:PLX$1.54 +0.09 (+6.21%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$1.58 +0.04 (+2.60%) As of 06/27/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Addition by Subtraction: Intel’s New Strategy Energizes Investors NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside QuantumScape Soars 30%: What Drove the Next-Gen EV Stock's Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
